Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum
Rhea-AI Summary
Apogee Therapeutics (Nasdaq: APGE) has announced its upcoming participation in the Stifel 2025 Virtual Immunology and Inflammation Forum. The company's management team will engage in a fireside chat scheduled for Tuesday, September 16, 2025, at 11:30 a.m. E.T.
Investors and interested parties can access both the live and archived versions of the fireside chat through the News & Events page in the Investors section of Apogee Therapeutics' website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, APGE gained 0.79%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 11:30 a.m. E.T.
A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest I&I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD), and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class profiles through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Apogee Therapeutics (APGE) presenting at the Stifel 2025 Virtual Immunology Forum?
How can investors access Apogee Therapeutics' (APGE) Stifel Forum presentation?
What type of presentation will Apogee Therapeutics (APGE) give at the Stifel Forum?
Where is the Stifel 2025 Immunology Forum being held?
